Somnoware announced today that the company is launching a program to monitor and assist in the clinical triage of patients impacted by the Philips Respironics device recall. The program will be deployed in collaboration with Kaiser Permanente.

Somnoware’s partnership with Philips enables patient data to be used to promote patient health. As part of the initiative, Kaiser patients impacted by the recall are enrolled into a five-year health monitoring program to help identify adverse health consequences related to the use of recalled Phillips Respironics PAP devices.

Using Somnoware’s platform, surveys will be deployed to impacted patients on a routine schedule. With Somnoware’s streamlined, data-driven processes, patients’ responses can be automatically categorized to assist with appropriate clinical triage.

“Somnoware is proud to partner with Kaiser Permanente to help patients impacted by the Philips Respironics recall,” said Subath Kamalasan, Somnoware CEO. “The sleep medicine community, including large hospital systems, are in need of innovative solutions to monitor and help patients that have been impacted. Our partnership illustrates Somnoware’s commitment to provide solutions to help customers, patients, and our device integration partners.”

On June 30, 2021, the U.S. Food and Drug Administration (FDA) alerted people who use Philips Respironics ventilators, BiPAP, and CPAP machines and their health care providers that Philips Respironics has recalled certain devices due to potential health risks.

In a message from the CEO, Roy Jakobs, Royal Philips CEO, stated, “Our first priority is to rebuild Philips’ reputation around patient safety and quality. We are fully committed to completing the Respironics recall and testing program in 2023. Across the company, we have assigned the highest priority to making the necessary step-up in patient safety and quality management …”

Updates on the recall can be found here.